Danny Hsu: Are Elastic Compression Stockings Ineffective in Preventing Post-Thrombotic Syndrome?
Danny Hsu, President of THANZ, shared on LinkedIn about a recent article by Jean-Philippe Galanaud et al, published in RPTH Journal:
”The Great Stocking Debate: It’s Not About ‘If,’ It’s About ‘How Much’
For years, the efficacy of Elastic Compression Stockings (ECS) in preventing Post-Thrombotic Syndrome (PTS) has been controversial.
Are they ineffective, or are they just sitting in the drawer?
This RPTH Journal publication sheds more light on the debate, courtesy of Dr Jean-Philippe Galanaud’s team.
A new prespecified analysis of the CELEST trial suggests that adherence is the independent predictor we’ve been looking for.
The Data: The ‘50%’ Threshold
This double-blind trial compared PTS rates at 2 years based on how often patients actually wore their stockings.
The results reveal a clear ‘tipping point’:
- < 50% Adherence: 38.4% PTS rate
- 50–79% Adherence: 24.5% PTS rate
- ≥ 80% Adherence: 27.5% PTS rate
Clinical Pearl: The “All or Nothing” Myth
Perfection isn’t required. Wearing ECS ≥50% of the time significantly decreased the risk of PTS (aOR=0.51).
Who Benefits the Most?
The study identified a specific phenotype where adherence yields the highest return.
Non-obese patients with extensive DVT (≥4 venous segments) saw a massive benefit:
- Adherent (≥50%): 29.8% developed PTS
- Non-Adherent: 54.3% developed PTS
Risk Factors for PTS Identified:
- Obesity (aOR=4.73)
- Extensive DVT (≥4 segments aOR=15.59)
- Patient height
The Verdict:
Adherence matters, but we can be realistic with our patients.
Aiming for at least 50% wear time makes a clinically significant difference, particularly for our high-risk patients with extensive proximal DVT.
Does this data change how you counsel patients on compression adherence?”
Title: Impact of Adherence on Elastic Compression Stockings Efficacy to Prevent Post-Thrombotic Syndrome: a Prespecified Analysis of the CELEST Study
Authors: Jean-Philippe Galanaud, Céline Genty-Vermorel, Béatrice Terriat, Audrey Stansal, Damien Lanéelle, Claire Grange, Myriam Martin, Francis Couturaud, Patrick Mismetti, Alexa Comte, Claire Eychenne, François Verrière, Jean-Luc Bosson, CELEST investigators
Read the Full Article on RPTH Journal

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 11, 2026, 21:44Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026
-
Jul 11, 2026, 21:43Sharing New Research in Hemophilia at ISTH 2026 – Novo Nordisk Medical US
-
Jul 11, 2026, 21:41Bianca Constantin: Don’t Miss the ISTH Early Career Committee Activities
-
Jul 11, 2026, 21:38Fateme Babaha: Don’t Miss Your Favorite ISTH 2026 Sessions
-
Jul 11, 2026, 21:11Farjah Algahtani: Learning, Sharing, and Collaborating at ISTH 2026
-
Jul 11, 2026, 19:56Louise St. Germain Bannon: A Fantastic Start to ISTH 2026 and the Future of Thrombosis Research
-
Jul 11, 2026, 19:38Lynn Kloeckner: Recognizing Kirsten Lacine’s Impact on the Stroke Survivor Journey
-
Jul 11, 2026, 19:19Rens De Groot: New Proteomic Evidence Reveals Early Hemolysis During ADAMTS13 Relapse in Immune TTP
-
Jul 11, 2026, 19:01Laurent Bertoletti: Honoring the Legacy of Guy Meyer and the INNOVTE Network at ISTH 2026